Streetbeat News

Products Services

NSRGY

Nestlé SA (OTC:NSRGY) plans to develop products that pair with popular weight-loss medications like Ozempic, Wegovy, and Mounjaro. The move comes amid concerns about the potential impacts these appetite-suppressing drugs might have on the food industry. Nestlé's CEO, Mark Schneider, stated that the company's portfolio will not be significantly affected as consumers will continue to consume coffee and pet food, two of the company’s major revenue streams.

Portfolio Pulse from Benzinga Neuro

October 20, 2023 | 9:39 am

AAPL

Apple TV+, a streaming platform of Apple Inc. (NASDAQ:AAPL), has reportedly ended 'The Problem With Jon Stewart' due to creative differences, particularly concerning the show's coverage of artificial intelligence and China. The cancellation has raised questions about Apple's stance on issues related to China, which accounts for about 20% of its sales. This comes amid growing concerns about a potential iPhone ban in China and the recent underperformance of the iPhone 15 range in the country.

Portfolio Pulse from Ananya Gairola

October 20, 2023 | 9:25 am

GILD

Gilead Sciences has presented new data at the 19th European AIDS Conference, demonstrating the strong clinical profile of its twice-yearly Sunlenca for adults with multi-drug resistant HIV.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 9:15 am

TSLA

Tesla Inc. has hinted at the possibility of developing a 'Plaid' version of its Model 3, according to a report by Electrek. The report suggests that the new model could feature an advanced suspension system, sport brakes, and lightweight, minimalist wheels. However, it remains unclear if a Plaid Model 3 is indeed in the works, and Tesla is expected to bring more clarity on the matter soon.

Portfolio Pulse from Benzinga Neuro

October 20, 2023 | 6:37 am

AAPL

NFLX

Apple Inc. (NASDAQ:AAPL) CEO Tim Cook attended a special screening of Martin Scorsese's latest film, 'Killers of the Flower Moon', which is set to premiere in theaters this Friday. This marks Apple's strategic move into the traditional film industry with high-profile theatrical releases. The film will be available for streaming on Apple TV+ after its worldwide theatrical release. This move challenges the streaming-first philosophy of industry leader Netflix Inc. (NASDAQ:NFLX).

Portfolio Pulse from Ananya Gairola

October 20, 2023 | 6:20 am

LCID

Lucid Group Inc (NASDAQ:LCID) will unveil its first SUV, the Gravity, at the LA Auto Show on November 16. The vehicle is expected to start production in late 2024 and will feature flexible seating options and a range 'beyond anything else on the market except Lucid Air.' The price range is yet to be disclosed. The company has sufficient capital for the start of Gravity's production, with total liquidity of approximately $6.25 billion at the end of Q2.

Portfolio Pulse from Anan Ashraf

October 20, 2023 | 5:04 am

TSLA

Tesla Inc (NASDAQ:TSLA) has increased the price of its Model X Plaid in the U.S. by $5,000 or 5.6%, now priced at $94,990. This comes a day after CEO Elon Musk spoke about reducing vehicle prices to make them more affordable amidst rising interest rates. Prices of all other models remain unchanged.

Portfolio Pulse from Anan Ashraf

October 20, 2023 | 4:47 am

MSFT

Microsoft Corporation's CEO, Satya Nadella, shared a letter to shareholders highlighting the company's strong fiscal year 2023 results, with record revenue of $211 billion and over $88 billion in operating income. LinkedIn, a Microsoft subsidiary, surpassed $15 billion in revenue for the first time. Nadella also outlined Microsoft's vision for a new era of AI and its impact on software and businesses globally. He mentioned Microsoft's commitment to enhancing security operations and its impact on various sectors, including gaming and web browsing.

Portfolio Pulse from Ananya Gairola

October 20, 2023 | 4:31 am

RANI

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) announced successful oral delivery of a monoclonal antibody, Humira® (adalimumab), via its high-capacity capsule, the RaniPill® HC, in a preclinical study. The RaniPill® HC has achieved a cumulative >90% success rate across multiple preclinical studies. The company has been shortlisted as a finalist in the 2023 Fierce Life Sciences Innovation Awards in the 'Drug Delivery Technology' category.

Portfolio Pulse from Happy Mohamed

October 19, 2023 | 8:14 pm

AEON

AEON Biopharma announced topline results from its Phase 2 trial of ABP-450 for the preventive treatment of episodic migraine. The treatment showed a positive effect but did not meet statistical significance versus placebo due to a higher-than-expected placebo response. However, the study demonstrated statistical significance on multiple secondary and exploratory endpoints. The data supports the decision to advance into Phase 3, anticipated in 2H 2024. An ongoing Phase 2 trial for the preventive treatment of chronic migraine has enrolled over 430 subjects, with enrollment completion expected in Q4 2023 and topline data in 2H 2024.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 8:08 pm